Leerink Swann Resumes Coverage on Genzyme (GENZ) with a Market Perform; Product & Pipeline Diversification Attractive
Tweet Send to a Friend
Leerink Swann resumes coverage on Genzyme (Nasdaq: GENZ) with a Market Perform rating. Price target $56.
Leerink analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink analyst says, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
